We are live on ! Find out more
NYMX

Nymox Pharmaceutical Corp

Delisted

NYMX was delisted on the 6th of July, 2023.

45 hedge funds and large institutions have $5.19M invested in Nymox Pharmaceutical Corp in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

36% more capital invested

Capital invested by funds: $3.8M → $5.19M (+$1.39M)

18% more funds holding

Funds holding: 3845 (+7)

0.3% more ownership

Funds ownership: 3.06%3.35% (+0.3%)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

33% less call options, than puts

Call options by funds: $27K | Put options by funds: $40K

Holders
45
Holders Change
+7
Holders Change %
+18.42%
% of All Funds
0.88%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
9
Reduced
11
Closed
3
Calls
$27K
Puts
$40K
Net Calls
-$13K
Net Calls Change
-$21K

NYMX Hedge Fund Activity: Q4 2019 in Review

45 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q4 2019, worth a combined $5.19M — up 36% from $3.8M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new NYMX positions and 3 closed out — a net gain of 7 holders — while 9 added to existing stakes and 11 trimmed.

The largest buyer was ExodusPoint Capital Management, opening a new position worth an estimated $194K. The largest seller was Millennium Management, cutting an estimated $219K.

  • 45 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q4 2019, up from 38 in Q3 2019.
  • Funds reported $5.19M of Nymox Pharmaceutical Corp stock for Q4 2019, up 36% quarter-over-quarter.
  • 10 funds opened new Nymox Pharmaceutical Corp positions in Q4 2019 and 3 closed out, a net change of +7 holders.
  • The largest Nymox Pharmaceutical Corp buyer in Q4 2019 was ExodusPoint Capital Management, an estimated $194K added.
  • The largest Nymox Pharmaceutical Corp seller in Q4 2019 was Millennium Management, an estimated $219K sold.

Based on aggregated 13F filings for Q4 2019.